BioSpace News Archive

Findings published in AACC’s journal Clinical Chemistry could be a major leap forward for prenatal testing.

Ampio Pharmaceuticals, Inc. announced their 2017 financial results during a conference call hosted on Wednesday, March 7th at 5:00 pm EST. Included below are highlighted disclosures from the corporate update and filed Annual report on Form 10K.

Healogics, Inc. announced that it has appointed Lynn Merritt to serve as Chief Human Resources Officer. Merritt joined Healogics in 2015 as Vice President, Learning and Development.

The gross offering proceeds to Vanda from the sale of the shares are expected to be approximately $93.5 million.

Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its pharmaceutical collaborator, Janssen Pharmaceutica N.V. (Janssen), has been granted Breakthrough Therapy Designation by the US FDA for erdafitinib in the treatment of metastatic urothelial cancer.

Supportive Data on All Candidates to be Highlighted in Poster Presentations at the Upcoming American Association for Cancer Research 2018 Annual Meeting Next Month

CIC Partners with HB Reavis, Europe’s Leading Innovative Workplace Provider, for Its Forthcoming 145K Square Foot Innovation Campus in Warsaw, Poland

Origenis GmbH, a German biotech company specializing in the discovery and development of highly selective small molecule kinase inhibitors for CNS disorders, today announced the appointment of Thomas Loeser as Chief Financial Officer (CFO).

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that an abstract highlighting X4P-001, the Company’s CXCR4 antagonist, has been selected for presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-18, 2018 in Chicago, IL.

– In the pivotal phase 3 CELESTIAL trial, CABOMETYX provided a statistically significant and clinically meaningful improvement versus placebo in overall survival (OS) –